Notice of Intent to Publish a Funding Opportunity Announcement for Generate A Precision Medicine Intergenerational Resource for the Study of Factor VIII Immunogenicity in Severe Hemophilia A:Clinical Coordinating Center
ID: 322896Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/322896
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the establishment of a Clinical Coordinating Center aimed at generating a Precision Medicine Intergenerational Resource for the study of Factor VIII immunogenicity in severe Hemophilia A. This initiative will utilize a UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement, allowing for a total of up to seven years of support, contingent upon the successful completion of core milestones over the initial three-year phase and subsequent four-year phase. The funding opportunity, which has an estimated total program funding of $2,060,000 and an award ceiling of $1,338,000, is designed to facilitate the development of a comprehensive resource that will enhance understanding and treatment of severe Hemophilia A. Interested applicants can reach out to Dr. Iman K. Martin at iman.martin@nih.gov or by phone at 301-435-0065 for further information, with the anticipated award date set for January 5, 2021.

    Point(s) of Contact
    Iman K. Martin, PhD, MPH, MS
    (301) 435-0065
    iman.martin@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the continuation of the NIDDK Hematology Central Coordinating Center (HCC) under a cooperative agreement. The HCC will collaborate with up to five Cooperative Centers of Excellence in Hematology (CCEH) to provide administrative support, develop communication strategies, and implement educational programs aimed at enhancing research in nonmalignant hematology. This initiative is crucial for fostering a national multidisciplinary research effort to study hematopoiesis and address nonmalignant hematologic diseases. The estimated total program funding is $1 million, with a single award anticipated, and the NOFO is expected to be published in December 2024, with applications due by March 2025. For further details, potential applicants should prepare to submit their proposals in alignment with the requirements outlined in the forthcoming NOFO.
    Cooperative Centers of Excellence in Hematology (CCEHs)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Cooperative Centers of Excellence in Hematology (CCEHs)" aimed at enhancing the nonmalignant hematology research community through a national network of resources and services. This program seeks to provide state-of-the-art expertise, enrichment activities, and small pilot funding to improve the quality and transparency of hematology research. With an estimated total program funding of $3,745,000 and the expectation of awarding five grants, interested applicants can reach out to Jennifer Norton at jenna.norton@nih.gov or by phone at 301-402-5496 for further details. The application process is set to begin with a synopsis posting on April 1, 2026, and will close on July 10, 2026, with awards anticipated by January 30, 2027.
    Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning communitY - Coordinating Center (KUH-FAMILY)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning communitY - Coordinating Center (KUH-FAMILY)." This initiative aims to establish a Coordinating Center that will unify and enhance various training and career development programs focused on recruiting, training, and retaining a national community of researchers in kidney, urologic, and hematologic diseases. The program is critical for fostering collaboration and innovation within these health fields, ultimately contributing to improved research outcomes. The estimated total funding for this cooperative agreement is $2,000,000, with one award expected to be made. Interested applicants can reach out to Christine Maric-Bilkan via email at christine.maric-bilkan@nih.gov for further information, with key deadlines including a synopsis close date of July 1, 2026, and an estimated project start date of February 1, 2027.
    HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity titled "HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials," aimed at establishing a Clinical Trial Center (CTC) and up to seven Clinical Centers (CCs) focused on heart failure with preserved ejection fraction (HFpEF). The initiative seeks to coordinate precision clinical trial activities, including master protocol development, project management, and recruitment oversight, while the CCs will be responsible for recruiting and retaining heart failure patients and conducting deep phenotyping protocols. This program is crucial for advancing personalized treatment approaches in heart failure, and while applications are not currently being solicited, interested parties are encouraged to prepare collaborative proposals ahead of the estimated synopsis posting on October 15, 2025, with a projected award date of May 1, 2026. For further inquiries, applicants can contact the HeartShare Team via email at nhlbiheartshare@mail.nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity for Coordination Center for the Alzheimer�s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium, aimed at advancing research in Alzheimer's disease genetics. This initiative, which follows the approval of the concept by the National Advisory Council on Aging, will invite applications under an open competition framework, expanding eligibility for potential applicants. The funding opportunity is critical for fostering collaborations and innovative projects in the field of health, with an estimated total program funding of $1.6 million and a maximum award ceiling of $1 million for the selected applicant. The NOFO is expected to be published in November 2024, with applications due by February 14, 2025, and awards anticipated to be made by September 1, 2025.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity for the Genome Sequencing Center as part of the Gabriella Miller Kids First Pediatric Research Program, aimed at advancing research into childhood cancer and congenital anomalies. This initiative will support the addition of data to existing resources, enhance data types as technologies evolve, and incorporate clinic-based data sources to better understand the genetic pathways of these disorders. With an estimated total program funding of $6.6 million, this cooperative agreement does not require cost sharing and is open to small businesses. Interested applicants are encouraged to prepare for the upcoming Notice of Funding Opportunity (NOFO), with an estimated synopsis posting date of July 30, 2025, and a closing date of October 30, 2025. For further inquiries, potential applicants can contact Dr. Concepcion R. Nierras at 301-435-5840 or via email at concepcion.nierras@nih.gov.
    Continued Development of the Gabriella Miller Kids First Pediatric Data Resource Center (U2C Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the Continued Development of the Gabriella Miller Kids First Pediatric Data Resource Center through a Cooperative Agreement. This initiative aims to enhance the Pediatric Data Resource, focusing on expanding data sharing, providing training in cloud-based computational analysis, and facilitating data use for researchers with limited bioinformatics training, ultimately contributing to advancements in understanding childhood cancer and congenital anomalies. The estimated total program funding is $5,200,000, with applications not currently being solicited; however, potential applicants are encouraged to prepare collaborative projects in anticipation of the upcoming Notice of Funding Opportunity (NOFO), which is expected to be published by July 30, 2025, with a closing date for synopsis on October 30, 2025. For further inquiries, interested parties may contact Dr. Concepcion R. Nierras at 301-435-5840 or via email at concepcion.nierras@nih.gov.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    Maternal Medications and Human Milk Research Center (M2HMRC)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity for the establishment of the Maternal Medications and Human Milk Research Center (M2HMRC) as part of its Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. This initiative aims to advance research on the impact of maternal medications on human milk composition and neonatal health outcomes by addressing knowledge gaps, integrating real-world evidence, developing innovative safety tools, and disseminating findings to a wide audience. The total estimated funding for this cooperative agreement is $2.5 million, with one award anticipated, and applications are expected to be solicited following the publication of the Notice of Funding Opportunity (NOFO) on November 3, 2025. Interested parties can reach out to Dr. Zhaoxia Ren at zren@mail.nih.gov or by phone at 240-463-5046 for further information.